ArticleJournal of the American Board of Family Medicine : JABFM2026
Do No Harm? Rethinking Urine Drug Screens in Treatment of Opioid Use Disorder.
Article in Journal of the American Board of Family Medicine : JABFM, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Point-of-Care Ultrasound, Prevention and Screening, Family Medicine Workforce, Navigating Systems, and Improving Patient Care.Journal of the American Board of Family Medicine : JABFMArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urine drug monitoring is widely used in outpatient addiction treatment, particularly for patients receiving medications for opioid use disorder (MOUD). While intended to support recovery and enhance clinical decision-making, the actual benefits of urine drug screening (UDS) remain uncertain. Evidence demonstrating improved patient outcomes is lacking, and the potential harms of routine screening are often underrecognized. These harms include false positives, patient stigma, racial bias, and trauma. UDS may also strain therapeutic relationships, particularly when used without transparency or patient consent. This essay calls for a more thoughtful, evidence-informed approach to drug screening in primary care. Clinicians should weigh the limitations of UDS and prioritize strategies that build trust, respect patient autonomy, and support long-term recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.